Revuforj (Revumenib) for Leukemia

Overview
Revuforj is approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute leukemia in adults and children aged 1 year and older with a lysine methyltransferase 2A gene (KMT2A) translocation. To be eligible, a person must have confirmed evidence of a KMT2A translocation through diagnostic testing. Revuforj is also known by its drug name, revumenib.

Revuforj belongs to the drug category of menin inhibitors. It works by targeting the menin protein, which plays a role in driving the abnormal gene activity associated with KMT2A translocations in leukemia. By blocking menin, Revuforj aims to stop the growth of cancerous cells.

How do I take it?
Prescribing information states that Revuforj is taken orally twice daily, either fasted or with a low-fat meal, at approximately the same time each day. Revuforj must be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Revuforj include nausea, hemorrhage (bleeding), increased phosphate levels, musculoskeletal pain, infections, elevated liver enzymes, febrile neutropenia (fever with low white blood cells), increased parathyroid hormone, bacterial infections, diarrhea, differentiation syndrome (a potentially severe complication), QT interval prolongation (a heart rhythm issue), decreased phosphate and potassium levels, increased triglycerides, decreased appetite, constipation, edema (swelling), viral infections, fatigue, and elevated alkaline phosphatase.

Rare but serious side effects may include differentiation syndrome, which can be fatal if not promptly treated, QT interval prolongation, and embryo-fetal toxicity (potential harm to unborn babies). People taking this medication should be monitored closely for these conditions, and females of reproductive potential should use effective contraception, according to the prescribing information.

For more information about this treatment, visit:

Revuforj (Revumenib) Tablets, for Oral Use — U.S. Food and Drug Administration

Revuforj FDA Approval History — Drugs.com